Moloney Securities Asset Management LLC lifted its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) by 48.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 98,626 shares of the company’s stock after purchasing an additional 32,126 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Ginkgo Bioworks were worth $167,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at approximately $30,000. Lake Street Financial LLC acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at approximately $31,000. Avantax Advisory Services Inc. acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at approximately $31,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Ginkgo Bioworks in the 1st quarter valued at approximately $43,000. Finally, Claraphi Advisory Network LLC acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at approximately $34,000. 61.83% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently commented on DNA. BTIG Research lowered their target price on Ginkgo Bioworks from $4.00 to $3.00 in a research report on Sunday, March 5th. Raymond James decreased their price target on Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, March 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.39.
Ginkgo Bioworks Stock Up 3.1 %
Insider Buying and Selling at Ginkgo Bioworks
In other Ginkgo Bioworks news, major shareholder Barry Canton sold 151,530 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $1.86, for a total transaction of $281,845.80. Following the completion of the transaction, the insider now directly owns 16,497,505 shares of the company’s stock, valued at approximately $30,685,359.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, major shareholder Barry Canton sold 151,530 shares of the firm’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $1.86, for a total transaction of $281,845.80. Following the completion of the sale, the insider now directly owns 16,497,505 shares of the company’s stock, valued at approximately $30,685,359.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Reshma P. Shetty sold 37,650 shares of the firm’s stock in a transaction on Wednesday, April 5th. The stock was sold at an average price of $1.22, for a total value of $45,933.00. Following the sale, the insider now directly owns 13,767,604 shares of the company’s stock, valued at $16,796,476.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,794,711 shares of company stock valued at $4,931,688. 17.47% of the stock is owned by corporate insiders.
Ginkgo Bioworks Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Delta Airlines Is Ready To Fly Higher
- Global Payments Climbs After Goldman Sachs Upgrade
- Fastenal Is At A Critical Turning Point
- 3 Healthcare Stocks Insiders Are Buying
- Novo Nordisk Charges Higher and Could be Just Getting Started
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
